正在加载视频...

视频加载失败

We’ve closed a fully-subscribed $80 million financing to support our ongoing clinical trial in optic neuropathies and advancement of our Partial Epigenetic Reprogramming platform across multiple indications. Read more:

14,044 次观看 • 3 个月前 •via X (Twitter)

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频